The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

The Potential of Ibrutinib Combinations for the Treatment of CLL

Javier Pinilla-Ibarz, MD, PhD
Published Online: 1:10 PM, Fri June 16, 2017

Javier Pinilla-Ibarz, MD, PhD, associate member, Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center, discusses ongoing research with ibrutinib (Imbruvica) in chronic lymphocytic leukemia. 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.